|
Sentinel node (disorder)
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
One‑step nucleic acid amplification (OSNA) targeting cytokeratin 19 (CK19) mRNA expression and pathological examination are widely used for the intraoperative diagnosis of sentinel node (SN) metastasis.
|
31638213 |
2019 |
|
Sentinel node (disorder)
|
0.100 |
Biomarker
|
disease |
BEFREE |
The epithelial cells were positive for CK19 but the one-step nucleic acid amplification assay revealed negative results for the axillary SLNs.
|
30756183 |
2019 |
|
Sentinel node (disorder)
|
0.100 |
Biomarker
|
disease |
BEFREE |
KRT19 is a well-established epithelial CSC marker that is used clinically to identify metastatic breast cancer cells in sentinel lymph node biopsies.
|
31311889 |
2019 |
|
Sentinel node (disorder)
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
TTL (defined as the total number of CK19 mRNA copies in all positive SLN) correlates with disease free survival (HR, 1.08; p = 0.000004), with local recurrence disease free survival (HR = 1.07; p = 0.0014) and overall survival (HR: 1.08, p = 0.0032), clearly defining a low-risk group (TTL <2.5 × 10<sup>4</sup> CK19 mRNA copies/μL) versus a high-risk group (>2.5 × 10<sup>4</sup> CK 19 mRNA copies/μL).
|
28254641 |
2017 |
|
Sentinel node (disorder)
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
A cut-off of 2150 cytokeratin 19 mRNA copy number in sentinel lymph node may be a powerful predictor of non-sentinel lymph node status in breast cancer patients.
|
28187209 |
2017 |
|
Sentinel node (disorder)
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cytokeratin 19 expression in early oral squamous cell carcinoma and their metastasis: Inadequate biomarker for one-step nucleic acid amplification implementation in sentinel lymph node biopsy procedure.
|
28644540 |
2017 |
|
Sentinel node (disorder)
|
0.100 |
Biomarker
|
disease |
BEFREE |
In two SLNs from the same patient, histopathological examination revealed the presence of benign epithelial inclusions that were CK19 positive; both SLNs yielded a positive result in the OSNA assay (true-false positive).
|
27498395 |
2016 |
|
Sentinel node (disorder)
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Intraoperative Sentinel Lymph Node Evaluation: Implications of Cytokeratin 19 Expression for the Adoption of OSNA in Oral Squamous Cell Carcinoma.
|
27393570 |
2016 |
|
Sentinel node (disorder)
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
CK19 mRNA in blood can predict non-sentinel lymph node metastasis in breast cancer.
|
27105542 |
2016 |
|
Sentinel node (disorder)
|
0.100 |
Biomarker
|
disease |
BEFREE |
We aimed to determine the effectiveness of CK19 mRNA copy number and tumour related factors in predicting non-sentinel axillary nodal involvement, in order to facilitate the formulation of local treatment guidelines for axillary clearance (ANC) following intra-operative analysis of the sentinel node biopsy (SNB) using one-step nucleic acid amplification (OSNA).
|
26979647 |
2016 |
|
Sentinel node (disorder)
|
0.100 |
Biomarker
|
disease |
BEFREE |
Systematic review and meta-analysis of cytokeratin 19-based one-step nucleic acid amplification versus histopathology for sentinel lymph node assessment in breast cancer.
|
24536007 |
2014 |
|
Sentinel node (disorder)
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Additional analysis was done to investigate how cytokeratin 19 mRNA copy number affects prediction of non-sentinel node positivity.
|
24630617 |
2014 |
|
Sentinel node (disorder)
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
A new clinical cut-off of cytokeratin 19 mRNA copy number in sentinel lymph node better identifies patients eligible for axillary lymph node dissection in breast cancer.
|
24906358 |
2014 |
|
Sentinel node (disorder)
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The frequency of non-sentinel lymph node metastasis (p < 0.0001) and the total number of lymph node metastases (p < 0.0001) increased with the amount of cytokeratin 19 mRNA on OSNA assay.
|
22203582 |
2013 |
|
Sentinel node (disorder)
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Omission of axillary lymph node dissection could be proposed in patients presenting a sentinel lymph node with a cytokeratin 19 mRNA copy number <2000 and a Luminal tumor phenotype.
|
23533593 |
2013 |
|
Sentinel node (disorder)
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
It measures cytokeratin19 (CK19) mRNA copy numbers in homogenized samples of SLN; CK19 has been chosen for identifying node metastasis because most breast cancers express this molecule.
|
23779101 |
2013 |
|
Sentinel node (disorder)
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Considering positive SLNs as '++' (CK19 mRNA copy number>5000), '+' (250 < CK19 mRNA copy number <5000) and positive by inhibition in the OSNA group and macro-, micrometastases and isolated tumor cells in the histopathology group, no difference in SLN involvement rate was found between the two groups with 29.0% and 29.9% of positive SLNs, respectively.
|
23661291 |
2013 |
|
Sentinel node (disorder)
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
TTL is defined as the amount of CK19 mRNA copies number in all positives SLN (copies/μL).
|
23576079 |
2013 |
|
Sentinel node (disorder)
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The CK19 mRNA copy number (≥1.0 × 10(5)) in the SLN was the only independent predictor of ≥4 LN metastases (P=0.014).
|
22929881 |
2012 |
|
Sentinel node (disorder)
|
0.100 |
Biomarker
|
disease |
BEFREE |
Recently, a new, highly specific and sensitive molecular procedure has been developed, based on cytokeratin 19 messenger RNA amplification, which allows for fast and effective intraoperative evaluation of the SN.
|
21326035 |
2011 |
|
Sentinel node (disorder)
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
A slight increase (35-40%) in CK19 and HER3 expression was observed in the tumors of patients with SLN metastases compared to those of patients without metastases, even if neither CK19 expression nor HER3 expression allowed to distinguish patients with micrometastases from patients with macrometastases.
|
18409145 |
2008 |
|
Sentinel node (disorder)
|
0.100 |
Biomarker
|
disease |
BEFREE |
We tested the suitability of a quantitative cytokeratin 19 (CK19) mRNA one step nucleic acid amplification (OSNA#) technique (OSNA-CK19) for intra-operative SN analysis.
|
18324628 |
2008 |
|
Sentinel node (disorder)
|
0.100 |
Biomarker
|
disease |
BEFREE |
The optimal two-gene combination, mammaglobin and cytokeratin 19, detected clinically actionable metastasis in breast SLNs with 90% sensitivity and 94% specificity.
|
16049304 |
2005 |